-- Lumos Diagnostics Holdings (ASX:LDX) has expanded an agreement with WellStreet Urgent Care to roll out its FebriDx rapid point-of-care test to an additional 43 locations from a single initial site, according to a Tuesday filing with the Australian bourse.
The expanded rollout will take place over the next two months, and once it is completed, Lumos expects WellStreet to launch FebriDx at all of the remaining outlets in its network of 163 urgent care locations, per the filing.
The increased volume and enhanced payor visibility from the expanded rollout should also strengthen the company's position in future contract negotiations with other health care providers, Lumos said.